Current Issue

View Larger Image

Past Issues Free Subscriptions
Sponsored
Keywords



GEN News Highlights

Back to Item »

After Panel’s Vote, Fate of Avastin for MBC in U.S. Rests with FDA Commissioner

Overall consensus of agency and CDER was that drug's benefits do not outweigh the risks.

Forward this item to a colleague:
Your name
Your email
(Separate multiple addresses by commas)
 
Colleague's email
(Separate multiple addresses by commas)
 
Personal Message
(optional)
 
 
 

GEN Poll

More » Poll Results » Archive »

The Price of BRCA Testing

Is getting a genetic test worth the multi-thousand dollar price?

Suggest a Poll